Reneo Pharmaceuticals Stock Debt To Equity
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
Reneo Pharmaceuticals fundamentals help investors to digest information that contributes to Reneo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reneo Stock. The fundamental analysis module provides a way to measure Reneo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reneo Pharmaceuticals stock.
Reneo |
Reneo Pharmaceuticals Company Debt To Equity Analysis
Reneo Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Reneo Pharmaceuticals Debt To Equity | 0.01 % |
Most of Reneo Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reneo Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Reneo Pharmaceuticals has a Debt To Equity of 0.011%. This is 99.98% lower than that of the Biotechnology sector and 99.94% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.98% higher than that of the company.
Reneo Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reneo Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reneo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reneo Pharmaceuticals by comparing valuation metrics of similar companies.Reneo Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
Reneo Fundamentals
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (15.01 M) | |||
| Shares Outstanding | 3.34 M | |||
| Shares Owned By Insiders | 5.19 % | |||
| Shares Owned By Institutions | 87.75 % | |||
| Number Of Shares Shorted | 3.4 M | |||
| Price To Book | 0.79 X | |||
| EBITDA | (82.23 M) | |||
| Net Income | (77.39 M) | |||
| Cash And Equivalents | 126.85 M | |||
| Cash Per Share | 5.18 X | |||
| Total Debt | 973 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 15.84 X | |||
| Book Value Per Share | 2.30 X | |||
| Cash Flow From Operations | (63.68 M) | |||
| Short Ratio | 27.39 X | |||
| Earnings Per Share | (16.80) X | |||
| Target Price | 2.25 | |||
| Beta | 0.22 | |||
| Market Capitalization | 6.08 M | |||
| Total Asset | 107.44 M | |||
| Retained Earnings | (218.47 M) | |||
| Working Capital | 88.44 M | |||
| Net Asset | 107.44 M |
About Reneo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reneo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reneo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reneo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |